
Progyny (PGNY) Stock Forecast & Price Target
Progyny (PGNY) Analyst Ratings
Bulls say
Progyny is supported by a differentiated fertility and family-building platform that combines Smart Cycles, a curated specialist network, and high-touch care advocacy to drive superior clinical outcomes and measurable ROI for employers. The CalPERS selection, effective July 1, 2027, validates that model after a rigorous review, while strong retention above 99%, a win rate above 50% on competitive deals, and a $8 bln TAM point to durable share gains and substantial underpenetration. Financially, 1Q26 revenue and EBITDA beat consensus, guidance was raised to $1.365B-$1.405B and $232M-$244M, and the company’s strong cash flow plus share repurchases reinforce confidence in long-term value creation.
Bears say
Progyny is facing a fundamentally weaker outlook because elevated attrition, utilization pressure, and a potential economic downturn could reduce membership levels and discourage employers from adopting fertility benefit plans. Competitive threats from traditional insurers and emerging start-ups, along with slower expansion into adjacent services and slower-than-expected new solution revenue, could further pressure growth and make revenue assumptions too aggressive. Sentiment is also vulnerable to a volatile political backdrop, as uncertainty around reproductive rights and unfavorable socioeconomic conditions may weigh on demand and lower utilization.
This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.
Progyny (PGNY) Analyst Forecast & Price Prediction
Start investing in Progyny (PGNY)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Progyny (PGNY) Forecast
Progyny (PGNY) Analyst Forecast & Price Prediction
Start investing in Progyny (PGNY)
Order type
Buy in
Order amount
Est. shares
0 shares